Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Imaging Studies III: Computed Tomography01:27

Imaging Studies III: Computed Tomography

251
DefinitionComputed Tomography (CT) of the genitourinary (GU) tract is a non-invasive imaging modality that utilizes X-rays and computer processing to generate detailed cross-sectional images of the urinary system, encompassing the kidneys, ureters, bladder, and adjacent structures such as the adrenal glands.PurposeCT scans of the GU tract serve several diagnostic and therapeutic purposes, including:Diagnosis of Urinary Tract Diseases: Detects kidney stones, tumors, cysts, and congenital...
251
Imaging Studies IV: Magnetic Resonance Imaging01:27

Imaging Studies IV: Magnetic Resonance Imaging

212
Introduction:Magnetic Resonance Imaging, or MRI, can include a specialized imaging technique of the urinary system known as Magnetic Resonance Urography (MRU). This radiation-free technique uses strong magnetic fields and radio waves to produce detailed images with the help of a computer. MRU is particularly effective for visualizing fluid-filled structures like the kidneys, ureters, and bladder.Applications of MRI in the Genitourinary SystemKidneys and Ureters: MRI detects tumors, cysts,...
212
Brain Imaging01:14

Brain Imaging

629
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans),  magnetic resonance imaging (MRI),  functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
629
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

460
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
460
Imaging Studies I: CT and MRI01:14

Imaging Studies I: CT and MRI

758
Introduction: MRI and CT scans are crucial advancements in medical imaging techniques, playing a vital role in diagnosing conditions related to the gastrointestinal (GI) system. Each scan serves distinct purposes, targets specific areas, and requires unique nursing duties.
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
758

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Characterisation of Posterior Predominant Amyloid PET Binding Across Multiple Cohorts.

bioRxiv : the preprint server for biology·2026
Same author

Prior Traumatic Brain Injury and Alzheimer Disease Blood Biomarkers.

JAMA neurology·2026
Same author

Identification of patients receiving amyloid-targeting therapies in observational studies using amyloid PET trajectories: Insights from LEADS.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Development and validation of a harmonized memory score for multicenter Alzheimer's disease and related dementia research.

Alzheimer's research & therapy·2026
Same author

Association of cognitive impairment and APOE ε4 with Centiloids in Hispanic and non-Hispanic White cohorts.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Genetic architecture of the limbic white matter microstructure in aging and Alzheimer's Disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Greater choroid plexus volume is linked to poor sleep, neurodegeneration, and cognitive deficits in older adults: Evidence from the IGNITE Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Plasma-based neurobiological protein biomarkers as predictors of dementia progression: Insights from longitudinal aging study in India - Diagnostic assessment of dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Neuropathology-specific language features in primary progressive aphasia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Dementia blood biomarkers in the context of post-stroke cognitive outcomes: Systematic review and evidence synthesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 8, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

751

阿尔茨海默氏症成像联盟

Konstantinos Chiotis1, Ganna Blazhenets1, Ani Eloyan2

  • 1Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 23, 2025
PubMed
概括
此摘要是机器生成的。

新的阿尔茨海默氏症治疗方法,如阿杜卡努马布和莱卡内马布,在观察性研究中有效地清除了粉样β (Aβ) 病理. 虽然tau水平和认知能力下降没有显著变化,但Aβ降低显著,支持治疗评估的观察数据.

更多相关视频

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

11.0K
Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

40.8K

相关实验视频

Last Updated: Jan 8, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

751
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

11.0K
Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

40.8K

科学领域:

  • 神经学 神经学
  • 药理学 药理学是指药理学的学科.
  • 生物标志物 生物标志物

背景情况:

  • 针对粉样β (Aβ) 病理的单克隆抗体在临床试验中证明了位参与和Aβ清除.
  • 已批准的Aβ向疗法需要现实世界的观察性研究来评估临床影响.

研究的目的:

  • 评估阿杜卡努马布和莱卡涅马布对Aβ和tau病理和早期阿尔茨海默病 (EOAD) 的认知衰退的影响.
  • 使用生物标志物和临床数据,将治疗轨迹与未经治疗的匹配队列进行比较.

主要方法:

  • 从LEADS队列中对20名EOAD参与者 (阿杜卡努马布,莱卡内马布或两者) 的分析.
  • 纵向Aβ和tauPET成像,认知评估 (CDR-SB) 和零碎回归建模.
  • 与1:3匹配的未经治疗的LEADS队列进行比较.

主要成果:

  • 在接受治疗的参与者中观察到治疗后显著的Aβ负担减轻 (p < 0.001).
  • 在接受治疗的组中,tau负荷或CDR-SB轨迹没有显著变化.
  • 在治疗与未治疗组中,CDR-SB增长趋势较慢 (p=0.07) 和Aβ显著降低 (p < 0.001).

结论:

  • 证实了与第三阶段试验相比的优异的目标参与率和Aβ清除率.
  • 使用生物标志物数据的观察性研究对于评估治疗疗效非常有价值,它补充了随机试验.
  • 该研究不足以在短时间的随访期间检测认知益处.